Middle East & Africa Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User

Description

List of Tables

The Middle East & Africa cell and gene therapy market was valued at US$ 129.17 million in 2023 and is projected to reach US$ 469.34 million by 2031; it is estimated to record a CAGR of 17.5% from 2023 to 2031.

Automation of Cell and Gene Therapy Manufacturing Services Boosts Middle East & Africa Cell and Gene Therapy Market

Incorporating automation in cell and gene therapy manufacturing can lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices designed to boost the automation of most sequential unit operations for a CAR-T process within a single system. With the rise in demand for cell and gene therapies, the production of cell and gene therapy products has shifted from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to commercialization has propelled the demand for automation in commercial manufacturing. Further, government agencies are adopting automation in the manufacturing of cell therapies to increase national production capabilities. Thus, automation of cell and gene therapy manufacturing services is expected to bring new trends in the Middle East & Africa cell and gene therapy market in the coming years.

Middle East & Africa Cell and Gene Therapy Market Overview

South Africa is a developing nation. The proper implementation of a cell therapy program in South Africa can result in the reduction of the high disease burden in the country; however, the cost of cell and gene therapy restricts South African patients' access to these therapies. Despite being technologically more advanced than other African nations, gene therapy manufacturing is still not widely available in South Africa. The most problematic aspects are the lack of funding, human resources, and awareness about therapy. Although the South African government has made efforts to support the biotechnology industry, cell therapy has not received enough attention. Moreover, the scientific and medical community is highly innovative and focused on cell and gene therapy.

Middle East & Africa Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Cell and Gene Therapy Market Segmentation

The Middle East & Africa cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Middle East & Africa cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Middle East & Africa cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Middle East & Africa cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Middle East & Africa cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Middle East & Africa cell and gene therapy market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Middle East & Africa cell and gene therapy market.

Product Code: BMIRE00031473

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Middle East & Africa Cell and Gene Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Middle East & Africa Cell and Gene Therapy Market - Key Market Dynamics

5.1 Cell and Gene Therapy Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
- 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.3 Market Restraints
- 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Companies
5.5 Future Trends
- 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Middle East & Africa Market Analysis

6.1 Overview Middle East and Africa Cell and Gene Therapy Market Overview
6.2 Middle East & Africa Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
6.3 Cell and Gene Therapy Market Forecast Analysis

7. Middle East & Africa Cell and Gene Therapy Market Analysis - by Type

7.1 Cell Therapy
- 7.1.1 Overview
- 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Gene Therapy
- 7.2.1 Overview
- 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Middle East & Africa Cell and Gene Therapy Market Analysis - by Services

8.1 Process Development
- 8.1.1 Overview
- 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.2 cGMP Manufacturing
- 8.2.1 Overview
- 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Regulatory Services
- 8.3.1 Overview
- 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Bioassay Services
- 8.4.1 Overview
- 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Middle East & Africa Cell and Gene Therapy Market Analysis - by Scale

9.1 Pre-Commercial/R&D Manufacturing
- 9.1.1 Overview
- 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Commercial Scale Manufacturing
- 9.2.1 Overview
- 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Middle East & Africa Cell and Gene Therapy Market Analysis - by Service Providers

10.1 CDMOs
- 10.1.1 Overview
- 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
10.2 CMOs
- 10.2.1 Overview
- 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Middle East & Africa Cell and Gene Therapy Market Analysis - by End User

11.1 Contract Research Organizations
- 11.1.1 Overview
- 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.2 Pharmaceutical and Biopharmaceutical Companies
- 11.2.1 Overview
- 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Academic and Research Institutes
- 11.3.1 Overview
- 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Middle East & Africa Cell and Gene Therapy Market - Country Analysis

12.1 Middle East and Africa Cell and Gene Therapy Market, by Key Country - Revenue (2023) (US$ Million)
- 12.1.1 Middle East and Africa Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 Middle East and Africa: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.2 South Africa: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.2.1 South Africa: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.2.1.1 South Africa: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.2.1.2 South Africa: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.2.2 South Africa: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.2.3 South Africa: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.2.4 South Africa: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.2.5 South Africa: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.3 Saudi Arabia: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.3.1 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.3.1.1 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.3.1.2 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.3.2 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.3.3 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.3.4 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.3.5 Saudi Arabia: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.4 United Arab Emirates: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.4.1 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.4.1.1 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.4.1.2 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.4.2 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.4.3 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.4.4 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.4.5 United Arab Emirates: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.5 Rest of Middle East and Africa: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.5.1 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.5.1.1 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.5.1.2 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.5.2 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.5.3 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.5.4 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.5.5 Rest of Middle East and Africa: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Cell and Gene Therapy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Thermo Fisher Scientific Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Merck KGaA
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Charles River Laboratories International Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Lonza Group AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 WuXi AppTec Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Takara Bio Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 FUJIFILM Holdings Corp
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Catalent Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Lotte Corp
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms